Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 8/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929030 | 1.00 | LRRK2 (0.42) | LRRK2MAPK1SYKKDRMAP4K1 | |
| SCHEMBL29929758 | 0.85 | LRRK2 (0.44) | LRRK2MAPK1SYKKDRMAP4K1 | |
| SCHEMBL26980380 | 0.85 | LRRK2 (0.44) | LRRK2MAPK1SYKKDRMAP4K1 | |
| SCHEMBL29929725 | 0.84 | CCNT1 (0.41) | LRRK2MAPK1SYKKDRMAPK3 | |
| SCHEMBL26980444 | 0.84 | CCNT1 (0.41) | LRRK2MAPK1SYKKDRMAPK3 | |
| SCHEMBL29113546 | 0.83 | LRRK2 (0.39) | LRRK2MAPK1SYKKDRMAPK3 | |
| SCHEMBL29113545 | 0.83 | LRRK2 (0.36) | LRRK2MAPK1SYKKDRMAPK3 | |
| SCHEMBL29929431 | 0.81 | EGFR (0.42) | — | |
| SCHEMBL26980771 | 0.81 | EGFR (0.42) | — | |
| SCHEMBL29929221 | 0.78 | JAK3 (0.46) | LRRK2SYKKDRMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | LRRK2 2250/4885MAPK1 3672/4885SYK 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.